MX2021011760A - Metodos para el tratamiento de canceres usando antisentido. - Google Patents

Metodos para el tratamiento de canceres usando antisentido.

Info

Publication number
MX2021011760A
MX2021011760A MX2021011760A MX2021011760A MX2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A
Authority
MX
Mexico
Prior art keywords
methods
antisense
igf
receptor
compositions
Prior art date
Application number
MX2021011760A
Other languages
English (en)
Inventor
Douglas C Hooper
David W Andrews
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021011760A publication Critical patent/MX2021011760A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a composiciones y métodos para tratar cánceres usando ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina (IGF-1R). El AS se puede administrar a los pacientes de manera sistémica o se puede usar para producir una vacuna de células cancerosas autólogas. En modalidades, los AS se proveen en una cámara de biodifusión irradiada implantable que comprende células tumorales y una cantidad eficaz de AS. Las cámaras se irradian e implantan en el abdomen de los sujetos y estimulan una respuesta inmune que ataca a los tumores distalmente. Las composiciones y métodos descritos en este documento pueden usarse para tratar muchos tipos diferentes de cáncer, por ejemplo, glioblastoma. En algunas modalidades, se proveen métodos para predecir la eficacia de los ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento similar a la insulina-1 (IGF-1R) en un sujeto.
MX2021011760A 2019-03-28 2020-03-27 Metodos para el tratamiento de canceres usando antisentido. MX2021011760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825516P 2019-03-28 2019-03-28
PCT/US2020/025217 WO2020198587A1 (en) 2019-03-28 2020-03-27 Methods for treating cancers using antisense

Publications (1)

Publication Number Publication Date
MX2021011760A true MX2021011760A (es) 2021-12-10

Family

ID=72609134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011760A MX2021011760A (es) 2019-03-28 2020-03-27 Metodos para el tratamiento de canceres usando antisentido.

Country Status (7)

Country Link
US (1) US20220195440A1 (es)
EP (1) EP3946287A4 (es)
JP (1) JP2022527473A (es)
AU (1) AU2020244865A1 (es)
CA (1) CA3134969A1 (es)
MX (1) MX2021011760A (es)
WO (1) WO2020198587A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509643A (ja) * 2000-09-29 2004-04-02 ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン アルキル化剤を用いた化学療法による治療に対する臨床反応を予測する方法
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods
EP1900825A1 (en) * 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
US20110217309A1 (en) * 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
NZ756820A (en) * 2017-03-09 2022-08-26 Univ Jefferson Methods and compositions for treating cancers using antisense

Also Published As

Publication number Publication date
EP3946287A1 (en) 2022-02-09
US20220195440A1 (en) 2022-06-23
EP3946287A4 (en) 2023-04-12
WO2020198587A1 (en) 2020-10-01
AU2020244865A1 (en) 2021-10-21
JP2022527473A (ja) 2022-06-02
CA3134969A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2019010725A (es) Metodos y composiciones para tratar canceres usando antisentido.
JP2019534308A5 (es)
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
JP2019504105A5 (es)
RU2016101057A (ru) Лечение рака головного мозга онколитическим аденовирусом
JP2015516496A5 (es)
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
JP2018530523A (ja) がんの放射線療法と免疫療法の組合せのための生体材料
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
EP1723963A3 (en) Hapten-conjugated tumour cells
MX2021005168A (es) Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
ATE359080T1 (de) Allogene zellkombination enthaltende implantate zur krebsbehandlung
Bausart et al. Combination of local immunogenic cell death-inducing chemotherapy and DNA vaccine increases the survival of glioblastoma-bearing mice
US20210283255A1 (en) Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation
Tong et al. Inhibiting human breast cancer cells (mcf-7) with alternating micro-current at intermediate frequency (acif) in vitro and in vivo
CA3196196A1 (en) Compositions of nanoparticles for treatment of cancer
WO2021127556A8 (en) Methods for treating cancer comprising low dose radiation
Kirova et al. Radiation-induced sarcomas following radiotherapy for breast cancer: six case reports and a review of the literature
CN108379562B (zh) 一种聚合物纳米佐剂及其制备方法和用途
CN106456687A (zh) 包含辣木叶提取物的放射线联合处理用组合物及利用其的治疗方法
MX2023004899A (es) Direccionamiento de src-3 en celulas inmunitarias como un inmunomodulador terapeutico para el tratamiento de cancer.
RU2285548C2 (ru) Способ лечения онкозаболеваний
CN101898012A (zh) 一种增强高强度聚焦超声诱导的抗肿瘤免疫应答的方法
RU2559130C1 (ru) Способ лечения неоперабельного немелкоклеточного рака легкого